Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2016 - 2025)

Vanda Pharmaceuticals' Other Operating Expenses history spans 16 years, with the latest figure at $5.3 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 28.15% to $5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.9 million, a 6.88% increase, with the full-year FY2025 number at $18.9 million, up 6.88% from a year prior.
  • Other Operating Expenses hit $5.3 million in Q4 2025 for Vanda Pharmaceuticals, up from $4.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for VNDA hit a ceiling of $6.8 million in Q3 2021 and a floor of $3.2 million in Q3 2023.
  • Historically, Other Operating Expenses has averaged $5.1 million across 5 years, with a median of $5.1 million in 2024.
  • Biggest five-year swings in Other Operating Expenses: tumbled 70.06% in 2021 and later grew 28.15% in 2025.
  • Tracing VNDA's Other Operating Expenses over 5 years: stood at $6.3 million in 2021, then increased by 1.04% to $6.3 million in 2022, then tumbled by 33.55% to $4.2 million in 2023, then fell by 2.07% to $4.1 million in 2024, then grew by 28.15% to $5.3 million in 2025.
  • Business Quant data shows Other Operating Expenses for VNDA at $5.3 million in Q4 2025, $4.4 million in Q3 2025, and $4.2 million in Q2 2025.